Biological Treatment Shows Promise for Alpha-Gal Syndrome Associated With Tick Bites
Recent research presented at the American College of Allergy, Asthma and Immunology indicates that the biologic drug omalizumab may help protect individuals suffering from alpha-gal syndrome, a red meat allergy triggered by lone star ticks.
🥗NutritionPhoto: Medical Xpress
Key points
- Omalizumab eliminated the need for epinephrine in study participants with alpha-gal syndrome.
- About one in three patients safely reintroduced some red meat into their diets.
- AGS symptoms often appear hours after eating, frequently delaying diagnosis.
A study presented at the American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting suggests that omalizumab, a biologic treatment already utilized for chronic hives and food allergies, may offer relief for people with alpha-gal syndrome (AGS). Transmitted primarily through lone star tick bites, AGS causes the body to react adversely to alpha-gal, a sugar found in mammal products like beef, pork, lamb, and certain dairy items. Because symptoms frequently appear hours after eating, diagnosing the condition can be difficult, affecting an estimated 96,000 to 450,000 Americans.
Study Findings on Omalizumab
The investigation followed 64 patients with AGS receiving omalizumab injections. Prior to the intervention, 81 percent had experienced anaphylaxis, and over half required epinephrine. While on the medication, none of the participants needed epinephrine for food reactions, and 95 percent reported that their symptoms occurred less frequently or with reduced severity. Furthermore, approximately one-third successfully reintroduced some mammal products into their diet. Adverse effects were generally mild, including joint pain, though two patients discontinued the treatment due to side effects.
Diagnostic Challenges and Mental Health Impact
A separate case report highlighted in the Annals of Allergy Asthma & Immunology detailed a 66-year-old man who experienced delayed respiratory symptoms and hives after consuming red meat and alcohol, illustrating how easily the condition can be missed. Researchers noted that patients often wait around seven years for a correct diagnosis, and approximately two-thirds experience anxiety or depression related to dietary restrictions.
What to know: While omalizumab may offer an extra layer of protection against accidental exposures, findings are based on observational studies of specific cohorts. Anyone suspecting they have alpha-gal syndrome should consult a board-certified allergist for formal blood testing and personal medical guidance.
Source Medical Xpress — medicalxpress.com/news/2026-11-patients-meat-allergy-omalizumab-symptom… ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…